CD79B CAR T-Cell Targeting in CD19-Negative Lymphoma

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current CAR T-cell therapies targeting CD19 antigen face significant challenges with relapse or progression due to CD19 antigen loss in B cell malignancies, necessitating the development of therapies against novel targets to improve patient outcomes.

Innovation Solution

Development of CD79b-specific chimeric antigen receptors (CARs) and monoclonal antibodies that bind specifically to CD79b, which are expressed in B cell malignancies and retained in CD19-negative tumors, combined with engineered CD79b-targeted CAR T cells to enhance therapeutic efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If CD19-targeted CAR T-cell therapy is used to treat B cell malignancies, then initial therapeutic response is achieved, but relapse or progression occurs due to CD19 antigen loss

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidantigen expression stability

Core Design Contradiction:

ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent changes the target antigen parameter from CD19 to CD79b. CD79b is a different molecular target on B cells that serves as an alternative antigen for CAR T-cell recognition. By switching the target parameter, the therapy can effectively recognize and eliminate B cell malignancies that have lost CD19 expression, thereby resolving the relapse problem while maintaining therapeutic efficacy

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the B cell target population by identifying and targeting CD79b as a distinct marker separate from CD19. This segmentation allows for the development of specialized CAR T-cell products that can target specific subsets of B cell malignancies, particularly those that have become CD19-negative while retaining CD79b expression

Inventive Principle:

Principle #1Segmentation

2Adaptability or versatility

If novel target CD79b is selected to overcome CD19 loss, then resistance to CD19-based therapy is overcome, but manufacturing and clinical validation complexity increases

Engineering Contradiction:

Improvetarget applicabilityVSAvoidtherapy development complexity

Core Design Contradiction:

Adaptability or versatilityVSDevice complexity

Solution Approach 1:

The patent establishes CD79b as a universal target for B cell malignancies. CD79b is expressed across various B cell cancers including diffuse large B cell lymphoma, follicular lymphoma, and mantle cell lymphoma, making it a multi-functional target that can address multiple disease types and CD19-loss scenarios. This universality simplifies the overall therapeutic strategy by providing a single alternative target with broad applicability

Inventive Principle:

Principle #6Universality (Multi-functionality)

Solution Approach 2:

The patent uses CD79b as an intermediary target that bridges the gap between CD19-positive and CD19-negative disease states. CD79b serves as a mediator that allows continuous targeting of B cell malignancies throughout disease progression, including relapse phases where CD19 is lost. This intermediary approach maintains therapeutic continuity without requiring completely new target discovery for each relapse event

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS12454574B2Anti-CD79B antibodies and chimeric antigen receptors and methods of use thereof

Publication Date: 2025.10.28 BOARD OF RGT THE UNIV OF TEXAS SYST

AI summary

Provided herein are CD79b antibodies and CD79b-specific chimeric antigen receptors (CARs). Further provided herein are T cells expressing the CD79b-specific CARs and methods of treating cancer by administering the CD79b-specific CAR T cells.